Brought by Mosaic Health and Central Virginia Health Services, this lawsuit alleges that in 2020 Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca coordinated to limit access to discounted diabetes drugs, harming providers serving patients with low incomes. The unanimous decision by a three-judge panel of the 2nd United States Circuit Court of Appeals overturns a lower court ruling that had previously dismissed the case.
The plaintiffs argue that the four rival pharmaceutical companies, which dominate the diabetes drug market, acted together to impose restrictions that boosted profits at the expense of vulnerable patients. Mosaic Health, which operates 22 clinics in New York, and Central Virginia Health Services, with 18 clinics in Virginia, claim the companies’ actions deprived them of critical savings, resulting in lost revenue. Their lawyers hailed the ruling as a “watershed moment” in their effort to hold pharmaceutical firms accountable for undermining the program’s purpose.
The case, Mosaic Health Inc v. Sanofi-Aventis U.S. LLC, now returns to the lower court for further proceedings.
To read how the pharmaceutical industry is a 1.5 trillion-dollar investment industry that is driven by the profits of its shareholders, see the ‘Laws of the Pharmaceutical Industry’ page on our website.
Study Finds Vitamin B3 and Green Tea Compound Help Aging Brain Cells Clean Up
August 14, 2025Majority of Americans Get More Than Half of Their Calories from Ultra-Processed Foods
August 14, 2025US Appeals Court Reinstates Drug-Price Conspiracy Lawsuit Against Sanofi and Other Pharma Companies
News
Drugmakers Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca must face a lawsuit from two health centers in the United States accusing them of conspiring to restrict drug discounts offered to community pharmacies that contract with providers serving low-income patients.
[Source: reuters.com]
[Image source: Adobe Stock]
Comment
Brought by Mosaic Health and Central Virginia Health Services, this lawsuit alleges that in 2020 Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca coordinated to limit access to discounted diabetes drugs, harming providers serving patients with low incomes. The unanimous decision by a three-judge panel of the 2nd United States Circuit Court of Appeals overturns a lower court ruling that had previously dismissed the case.
The plaintiffs argue that the four rival pharmaceutical companies, which dominate the diabetes drug market, acted together to impose restrictions that boosted profits at the expense of vulnerable patients. Mosaic Health, which operates 22 clinics in New York, and Central Virginia Health Services, with 18 clinics in Virginia, claim the companies’ actions deprived them of critical savings, resulting in lost revenue. Their lawyers hailed the ruling as a “watershed moment” in their effort to hold pharmaceutical firms accountable for undermining the program’s purpose.
The case, Mosaic Health Inc v. Sanofi-Aventis U.S. LLC, now returns to the lower court for further proceedings.
To read how the pharmaceutical industry is a 1.5 trillion-dollar investment industry that is driven by the profits of its shareholders, see the ‘Laws of the Pharmaceutical Industry’ page on our website.
Dr. Rath Health Foundation
Related posts
The Grand Canyon’s Water is Supposed to be Pristine. Scientists Just Found Pharmaceuticals in It
Read more